Key result
Spexin attenuates isoproterenol-induced myocardial injury and PANoptosis markers in rats.
Why the study?
Does intraperitoneal spexin treatment attenuate myocardial injury and reduce PANoptosis-associated markers, NINJ1, HMGB1, and neuropeptide Y in rats with isoproterenol-induced myocardial injury?
Does intraperitoneal spexin treatment attenuate myocardial injury and reduce PANoptosis-associated markers, NINJ1, HMGB1, and neuropeptide Y in rats with isoproterenol-induced myocardial injury?
In a rat model of isoproterenol-induced myocardial injury, spexin treatment was associated with reduced markers of PANoptosis, membrane damage-related inflammation (NINJ1, HMGB1), and neurohumoral stress (NPY).
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in rat myocardial injury; leaves open translation to human PANoptosis-targeted cardioprotection.
Acute myocardial injury is characterized by oxidative stress, inflammation, and convergent regulated cell-death responses. Spexin (SPX) is a pleiotropic neuropeptide involved in cardiovascular and metabolic regulation and has been reported to have antioxidant, anti-inflammatory, and cytoprotective effects. However, its role in PANoptosis-associated myocardial injury remains unclear. Because apoptosis, pyroptosis, and necroptosis may act in concert during myocardial damage, we examined whether SPX is associated with modulation of PANoptosis-related responses in an isoproterenol (ISO)-induced rat model. Myocardial injury was induced by subcutaneous ISO administration (100 mg/kg, twice at 24-h intervals), followed by intraperitoneal SPX treatment (35-70 µg/kg) for 7 days. Serum and myocardial tissues were analyzed for cardiac injury markers, inflammatory cytokines, oxidative stress indices, neuropeptide Y (NPY), and high-mobility group box 1 (HMGB1). Immunohistochemistry was used to assess nerve injury-induced protein 1 (NINJ1), cardiomyocyte markers, and PANoptosis-associated proteins related to apoptosis, pyroptosis, and necroptosis. ISO caused marked myocardial injury, inflammatory and oxidative imbalance, increased NINJ1 immunoreactivity and HMGB1 levels, elevated NPY levels, reduced NK2 homeobox 5 and cardiac troponin T immunoreactivity, and upregulation of PANoptosis-associated markers, including Cleaved Caspase-3/7, Cleaved Gasdermin-D, NOD-like receptor family pyrin domain-containing 3, phospho-receptor-interacting protein kinase 1/3, and phospho-mixed lineage kinase domain-like protein. Both SPX doses were associated with attenuation of several ISO-induced alterations; however, no consistent dose-dependent pattern was observed across the assessed outcomes. These findings support an association between SPX treatment and reductions in integrated cell-death-associated marker immunoreactivity, membrane damage-related inflammatory responses, and neurohumoral stress in experimental myocardial injury.
No takes yet. Share an insight, caveat, or question.
Altınbaş et al. (2026) studied Isoproterenol-induced acute myocardial injury. Spexin vs. Untreated isoproterenol-induced myocardial injury control was evaluated on Cardiac injury markers, inflammatory cytokines, oxidative stress indices, NPY, HMGB1, NINJ1, and PANoptosis-associated markers. Spexin (35-/kg for 7 days) attenuated isoproterenol-induced myocardial injury, HMGB1, NPY, NINJ1, and PANoptosis markers in rats without a consistent dose-dependent pattern.
Synapse has enriched 10 related papers. Consider them for comparative context: